Stoke Therapeutics Past Earnings Performance
Past criteria checks 0/6
Stoke Therapeutics has been growing earnings at an average annual rate of 13.1%, while the Biotechs industry saw earnings growing at 36.2% annually. Revenues have been growing at an average rate of 71.8% per year.
Key information
13.06%
Earnings growth rate
20.53%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 71.80% |
| Return on equity | -42.99% |
| Net Margin | -529.20% |
| Last Earnings Update | 31 Mar 2026 |
Recent past performance updates
Recent updates
Analysis Article • May 11
Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Are Pretty Bullish On The Stock After Recent Results
As you might know, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just kicked off its latest quarterly results with some very...
New Narrative • May 11
Phase III Trial And Payer Risks Will Shape Dravet Treatment Prospects
Catalysts About Stoke Therapeutics Stoke Therapeutics is a biotechnology company focused on RNA-based medicines, including zorevunersen for Dravet syndrome. What are the underlying business or industry changes driving this perspective?Seeking Alpha • May 01
Stoke Therapeutics: Zorevunersen Has Disease-Modifying Potential In Dravet Syndrome
Summary I initiate Stoke Therapeutics with a Buy rating, driven by late-stage progress for zorevunersen in SCN1A Dravet Syndrome. STOK's phase 3 EMPEROR trial for zorevunersen targets mid-2027 data and a rolling NDA submission in the first half of 2027. Three-year open-label data show durable seizure reduction and functional improvement, supporting disease-modifying potential for zorevunersen. STOK's $390.9M cash position, Biogen partnership, and low burn rate provide runway into mid-2028, mitigating near-term financing risk. Read the full article on Seeking AlphaAnalysis Article • Jan 12
Newsflash: Stoke Therapeutics, Inc. (NASDAQ:STOK) Analysts Have Been Trimming Their Revenue Forecasts
The analysts covering Stoke Therapeutics, Inc. ( NASDAQ:STOK ) delivered a dose of negativity to shareholders today, by...Analysis Article • Dec 05
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 36% But Its Business Still Trails The Industry
Despite an already strong run, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have been powering on, with a gain of...Analysis Article • Oct 09
Stoke Therapeutics, Inc. (NASDAQ:STOK) Held Back By Insufficient Growth Even After Shares Climb 39%
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 39% gain in the last month...Analysis Article • Aug 25
Improved Revenues Required Before Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock's 49% Jump Looks Justified
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares have continued their recent momentum with a 49% gain in the last month...Analysis Article • Aug 15
Stoke Therapeutics, Inc. (NASDAQ:STOK) Shares Could Be 25% Above Their Intrinsic Value Estimate
NasdaqGS:STOK 1 Year Share Price vs Fair Value Explore Stoke Therapeutics's Fair Values from the Community and select...Analysis Article • May 20
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) Shares Bounce 28% But Its Business Still Trails The Industry
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders would be excited to see that the share price has had a great...Analysis Article • Apr 16
Analysts Are More Bearish On Stoke Therapeutics, Inc. (NASDAQ:STOK) Than They Used To Be
Market forces rained on the parade of Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders today, when the analysts...Analysis Article • Apr 05
Stoke Therapeutics, Inc.'s (NASDAQ:STOK) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shares are down a considerable 27% in...Analysis Article • Feb 26
We're Hopeful That Stoke Therapeutics (NASDAQ:STOK) Will Use Its Cash Wisely
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...Seeking Alpha • Feb 16
Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer
Summary Stoke Therapeutics' RNA-based treatments for severe neurological and ophthalmic disorders, particularly zorevunersen for Dravet syndrome, show potential for long-term value beyond a single drug. Financials reveal high R&D spending and cash burn, but revenue growth from Acadia Pharmaceuticals collaboration suggests early monetization and potential non-dilutive funding. The Phase 3 EMPEROR study for zorevunersen is critical, with regulatory alignment and promising early data, but execution and long-term safety monitoring remain challenges. Stoke's broader pipeline, including treatments for SYNGAP1-related disorders, Rett syndrome, and Autosomal Dominant Optic Atrophy, could expand its market potential if RNA modulation proves broadly effective. Read the full article on Seeking AlphaAnalysis Article • Nov 08
Earnings Update: Stoke Therapeutics, Inc. (NASDAQ:STOK) Just Reported And Analysts Are Trimming Their Forecasts
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) just released its third-quarter report and things are looking bullish. Results...Analysis Article • Nov 06
Industry Analysts Just Made A Huge Upgrade To Their Stoke Therapeutics, Inc. (NASDAQ:STOK) Revenue Forecasts
Stoke Therapeutics, Inc. ( NASDAQ:STOK ) shareholders will have a reason to smile today, with the analysts making...Seeking Alpha • Sep 07
Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome
Summary STOK's zorevunersen shows strong efficacy in reducing seizures but has safety concerns, particularly elevated CSF protein levels, needing further monitoring. Dravet Syndrome market potential is significant, with 35,000 patients in key regions and existing treatments costing up to $96,000 annually. STOK has a solid cash runway for 7-8 quarters, with a Phase 3 trial expected to start soon, aiming for topline data by mid-2026. Despite recent stock gains, I may consider investing when Phase 3 trial enrollment is announced, given the promising genetic approach to Dravet Syndrome. Read the full article on Seeking AlphaAnalysis Article • Jul 22
We're Keeping An Eye On Stoke Therapeutics' (NASDAQ:STOK) Cash Burn Rate
Just because a business does not make any money, does not mean that the stock will go down. For example, although...Seeking Alpha • Jun 14
Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome
Summary Stoke Therapeutics' TANGO platform enhances RNA output to compensate for gene mutations causing severe genetic diseases. STOK primarily focuses on developing treatments for Dravet syndrome and autosomal dominant optic atrophy (ADOA). STK-001, a Phase 1/2 candidate for Dravet syndrome, shows promising clinical results with seizure reduction and cognitive improvements. Collaborations with ACAD involve significant milestones and potential royalty payments, enhancing its financial outlook. STOK's financials are strong, with a healthy cash runway and potential for significant royalty revenues, making it a promising investment. Read the full article on Seeking AlphaRevenue & Expenses Breakdown
Revenue & Expenses Breakdown
How Stoke Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 26 | 32 | -170 | 72 | 145 |
| 31 Dec 25 | 184 | -7 | 67 | 138 |
| 30 Sep 25 | 206 | 41 | 59 | 120 |
| 30 Jun 25 | 200 | 52 | 55 | 104 |
| 31 Mar 25 | 191 | 50 | 53 | 99 |
| 31 Dec 24 | 37 | -89 | 49 | 89 |
| 30 Sep 24 | 17 | -105 | 47 | 87 |
| 30 Jun 24 | 15 | -104 | 44 | 86 |
| 31 Mar 24 | 8 | -109 | 41 | 85 |
| 31 Dec 23 | 9 | -105 | 41 | 82 |
| 30 Sep 23 | 9 | -103 | 40 | 82 |
| 30 Jun 23 | 9 | -105 | 40 | 81 |
| 31 Mar 23 | 15 | -99 | 40 | 79 |
| 31 Dec 22 | 12 | -101 | 39 | 78 |
| 30 Sep 22 | 9 | -100 | 38 | 73 |
| 30 Jun 22 | 6 | -96 | 37 | 67 |
| 31 Mar 22 | 3 | -94 | 34 | 63 |
| 31 Dec 21 | 0 | -86 | 32 | 54 |
| 30 Sep 21 | 0 | -76 | 29 | 47 |
| 30 Jun 21 | 0 | -67 | 26 | 41 |
| 31 Mar 21 | 0 | -58 | 23 | 35 |
| 31 Dec 20 | 0 | -52 | 21 | 32 |
| 30 Sep 20 | 0 | -48 | 19 | 30 |
| 30 Jun 20 | 0 | -43 | 17 | 29 |
| 31 Mar 20 | 0 | -38 | 14 | 27 |
| 31 Dec 19 | 0 | -32 | 12 | 24 |
| 30 Sep 19 | 0 | -26 | 9 | 20 |
| 30 Jun 19 | 0 | -21 | 7 | 15 |
| 31 Mar 19 | 0 | -16 | 6 | 11 |
| 31 Dec 18 | 0 | -13 | 4 | 8 |
Quality Earnings: STOK is currently unprofitable.
Growing Profit Margin: STOK is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: STOK is unprofitable, but has reduced losses over the past 5 years at a rate of 13.1% per year.
Accelerating Growth: Unable to compare STOK's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: STOK is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (54.5%).
Return on Equity
High ROE: STOK has a negative Return on Equity (-42.99%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/15 20:10 |
| End of Day Share Price | 2026/06/12 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Stoke Therapeutics, Inc. is covered by 21 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Thomas Shrader | BTIG |
| Michelle Gilson | Canaccord Genuity |